An advantage of TRFIA was that it can exclude most sources of background fluorescence which frequently occurred in the conventional assays, and hence can greatly enhance signal-tonoise ratio. In the 1940's, for the first time, Coons used fluorescein to label an antibody to detect soluble pneumonia cocci amylose antigen, which established the fluorescence immunity assay (FIA). In 1979, Sonini and Hemmila put forward the theory of time-resolved fluoroimmunoassays (TRFIA) 1 on the basis of the interesting properties of rare earth ion complexes, i.e., large Stokes shift (280 nm), narrow emission spectrum (10 nm) and long fluorescent lifetime (10 -1000 µs).
Meanwhile, its application range was also extended. However, there still existed something unsolved. For example, the fluorescence was weaker than that in the DELFIA system; how to prepare the label with high relative immunological activity and high fluorescence intensity was not clear; storing conditions of BCPDA and the methods of measuring relevant parameters of the label were troublesome. Later, an intense and steady fluorescence emission was observed in promising lanthanide chelates 8, 9 when some cage-type chelates were used in immunoassays, but relative large particle sizes and surface character brought a certain number of questions in storing and applications. In addition, other new chelates were also reported by Ci and other authors. [10] [11] [12] [13] [14] [15] [16] [17] Nevertheless, as a directly luminescent lanthanide chelate for DSLFIA, some factors still remain open, such as the luminescence intensity, solubility and stability. Therefore, research on DSLFIA is still needed.
In this work, efforts were made for investigation of labeling techniques of DSLFIA. The conditions of labeling anti-HBs are discussed. The relevant parameters, the measurement methods, and the fluorescent characters were also studied in detail.
Experimental

Materials
BCPDA was synthesized according to previous work. 7 Donkey anti-hepatitis B surface (anti-HBs) and hepatitis B surface Ag (HBsAg) were purified by affinity isolation. Eu2O3 was purified to 99.999% by ourselves. RIA microtitration plate was obtained from FuRui Company (China); Sephadex G-50 was purchased from Changzheng Bio-chemistry Company (China); tri(hydroxymethyl)aminomethane (Tris) and Coomassie Brilliant Blue G-250 were purchased from Sigma Company. All other chemical reagents used throughout were analytical pure grade. Deionized water was used.
Apparatus
The nuclear magnetic resonance was performed on a Unity-400 MHz (American BIO-RAD Company). Elemental analysis was carried out on Elementar Analysensysteme (German GmbH VarioEL Company) and a 2120i Ion Chromatograph (American Dionex Company). The melting point was measured with an even-series thermal analysis instrument-DSC (American PerkinElmer Company). Absorption measurement and fluorescence spectrum detection were performed on a UV-3000 spectrophotometer (Shimadzu) and an RF-5000 fluorometer (Hitachi), respectively. Laser fluorescence lifetimes were measured on the device developed by ourselves. All other small model instruments were purchased from Chinese companies.
Methods
Labeling IgG of anti HBs antibody with BCPDA: 0.5 mg of IgG of anti HBs antibody was dissolved in 0.1 mol/L carbonate buffer at pH 9.1, and some amount of BCPDA was dissolved in dimethylformamide (DMF). After this, the obtained BCPDA solution was added to the IgG of anti HBs solution in five shares with one share every minute with stirring. Then the mixed solution was maintained at room temperature while stirring for 30 min. Finally, the BCPDA-labeled IgG of anti HBs antibody was collected by separating the reaction mixture through a Sephadex G-50 column (1.5 × 12 cm), which had been equilibrated and diluted with 0.05 mol/L NH4HCO3 at pH 8.0 in advance. 
Determination of the immunological activity of the label.
Relative immunological activity was defined as a ratio of IgG of anti HBs antibody remaining positive prior to labeling and after labeling at the same concentration. The immunological activity was measured by RIA. For example, 200 µl positive control serum, 200 µl negative control serum and 200 µl of BCPDAIgG of anti HBs antibody solutions which were obtained from diluting the above resulted BCPDA-IgG of anti HBs antibody solutions by 100, 1000, 5000 and 10000 fold, respectively, were added to the holes of the solid phase carrier in sequence. Then some balls coated with HBsAg were displaced in the holes and incubated for 2 h. Then, the balls were washed with distilled water thoroughly. After this, 200 µl labeled HBsAg I 125 was added in each hole, and the balls were immersed in the solutions. After 2 h of incubation, the balls were washed with distilled water thoroughly again, and the liquid part was removed. Finally, the balls were transferred to special tubes and cpm values of each ball was measured for 1 min on a γ-counter. Criterion for positivity. Labels cpm/negative serum cpm = P/N > 2.1 is defined as positivity (before calculation both labels cpm and negative serum cpm have to subtract background).
Results and Discussion
Characterization of BCPDA
Structure and purity of the BCPDA synthesized by our laboratory were identified by means of IR, 1 
Coomassie Brilliant Blue G-250 to quantify the concentration of anti-HBs in the labels
With several benzenes and aromatic nitrogens, BCPDA has stronger absorbance than protein at 280 nm. So UV absorbance determination is not suitable for solid phase TRFIA in the protein analysis, due to the severe interference from the BCPDA. Coomassie Brilliant Blue G-250 would become blue when it is bonded to protein at certain concentrations, which agrees with the Bill Law. Thus, by using the Coomassie Brilliant Blue G-250 method, the concentration of labeled antiHBs can be measured at 595 nm, while the BCPDA absorbance at 325 nm does not interfere. In addition, compared with the foline-phenol method, there were several advantages with the Coomassie Brilliant Blue G-250 method. For example, the operation is much easier and quicker and requires small consumption of samples. Therefore, the Coomassie Brilliant Blue G-250 method was chosen in this work for the protein concentration determination.
By using the method of Coomassie Brilliant Blue G-250 to detect the concentration of anti-HBs in the labeled anti-HBs, the linear range was 0.50 -40.0 µg/mL and the detection limit (three times of standard deviation of reagent blank/correlation coefficient) was 0.15 µg/mL.
Influence of labeling conditions on the immunological activity of anti-HBs
Immunoassay is based on the immunoreaction between antibody (Ab) and antigen (Ag). Immunological activity of the anti-HBs is very important after labeling. Therefore, the .1, respectively, we found that the results showed that, when the reaction buffer pH was 9.1, the anti-HBs retains its relatively higher immunological activity under alkaline conditions.
After increased the reaction time from 15 to 90 min, we found that the immunological activity of labeled anti-HBs decreased, while the molar ratio of BCPDA and the anti-HBs increased. As a compromise, 30 min was fixed for the reaction time.
Fixing other conditions and changing the volume percentage of DMF to the total reaction volume, we saw that, when the percentage of DMF decreased, a relatively higher immunological activity of label was observed. As the volume percentage of DMF was 2% of its total reaction volume, BCPDA became more soluble and the immunological activity of the anti-HBs became higher.
Influences on the label ratio and recovery of anti-HBs
The label ratio was defined as the molar ratio of BCPDA to anti-HBs in the label. It would affect the sensitivity of fluorescence detection. The goal of the experiment was to obtain high label ratio and high recovery of anti-HBs.
For the weight ratios of BCPDA to anti-HBs at 3:1, 2:1, 1:1 and 1:2, mole ratios of BCPDA/IgG were 59.3, 44.2, 36.3, and 29.8, respectively. Recovery of anti-HBs was 49.6, 56.9, 79.9, and 83.9, respectively. The labeled anti-HBs possessed the highest immunological activity when the weight ratio of BCPDA to anti-HBs is 1:2, but the label ratio of the BCPDA to anti-HBs became the lowest at the same condition. The increase of weight ratio resulted in the increase of the label ratio, the decrease of the anti-HBs recovery and the fall of immunological activity. Considering all possible factors, we selected the 1:1 weight ratio of BCPDA to anti-HBs in the experiment.
Due to their differences in molecular weight, BCPDA (617) and anti-HBS (156000) can be separated on Sephadex G-25, G-50 and G-100 resin separation column. The results indicated that Sephadex G-50 was more suitable than the other two. Thus Sephadex G-50 was used for the separation.
To ensure the stability and the immunological activity of the protein, the Sephadex G-50 separation column should work under alkalescent conditions. In this work, NH4HCO3 (0.1 mol/L, pH = 8.0) was chosen as the eluting solution.
Monitored by nucleic acid protein assay apparatus, the recovery of anti-HBs on Sephadex G-50 of column volumes 1.0 cm × 15 cm and 1.5 cm × 26.5 cm were compared. The results are shown in Table 1 . It seems that the 1.0 cm × 15 cm column is preferred. 3+ and its fluorescence spectrum BCPDA (Fig. 1) has two sulfonyl chloride groups, with which it can incorporate covalently with the dissociated amino of proteins. The two carboxyl and two aromatic nitrogen groups construct the chelating site for combining with lanthanide ion. In this work, Eu 3+ of a certain amount in Tris-HCl buffer was added to the carbonate buffer solution of BCPDA-anti-HBs and the mixture was a diluted properly. After this, the solution was incubated for 1 -2 h at 37˚C in order to form Eu 3+ -BCPDA-antiHBs and then stood at room temperature for 1 h before it was excited. The fluorescence emission spectrum bands of BCPDAanti-HBs-Eu 3+ at 589 nm and 612 nm can be seen in Fig. 2 . According to the spectrum of the BCPDA-anti-HBs-Eu 3+ , it can be concluded that europium ion complex would exhibit some special characteristics, such as very large Stokes shift (337 -612 nm), narrow emission spectrum (10 nm) and very long fluorescence lifetime (844 µs). The result of fluorescence measurement showed that the fluorescence intensity of the BCPDA-anti-HBs-Eu 3+ solution for 3 days at room temperature was almost unchangeable, which fully demonstrates the fluorescence stability of anti-HBs-BCPDA-Eu 3+ complex.
The reaction of BCPDA-anti-HBs with Eu
Fluorescence lifetime of BCPDA-anti-HBs-Eu 3+
Due to the structure of the BCPDA-anti-HBs-Eu 3+ complex, BCPDA can absorb the energy produced by the UV excitation light from the ground state to the excited state and the absorbed -kt . In this study, the fluorescence lifetime of antiHBs-BCPDA-Eu 3+ complex was measured by laser fluorescence lifetime measurement device which used exciting wavelength at 337.1 nm and detecting at delay time of 100 µs. The fluorescence lifetime of BCPDA-anti-HBs-Eu 3+ , τ, was determined to be 844 µs (Fig. 3) .
The influences on the fluorescence intensity
Anti-HBs-BCPDA-Eu 3+ solution was incubated under 37˚C at 0.25, 0.5, 1.0, 1.5, 2.0 and 2.5 h, respectively. The fluorescence intensity was the highest when the sample was incubated for 1.0 h.
The BCPDA-anti-HBs-Eu ) mol/L and the detection limit (three times of standard deviation of reagent blank/correlation coefficient) was 3.3 × 10 -11 mol/L.
BCPDA storing conditions
Special attention should be paid to the storing conditions for BCPDA throughout this work. It was proved that the bifunctional character of BCPDA did not change when it had been stored in a vaccum desiccator at -18˚C for 3 years and it could stand at room temperature for 24 h prior to being bound with anti-HBs. Thus it can be concluded that the sulfonyl chloride group is a functional group suitable for incorporating covalently with the amino group of proteins, and that the hydrolyzing property of it does not severely affect the storing of BCPDA.
Conclusions
The dissociated amino of protein incorporating covalently to BCPDA and the two carboxyl and two aromatic nitrogen groups bonding to Eu 3+ demonstrated that BCPDA would react with anti-HBs under relative mild conditions. This work also proved that the synthesized BCPDA structure was reliable. A method of Coomassie Brilliant Blue G-250 has been established to measure the concentration of labeled anti-HBs, which is used to control labeling procedure. The obtained BCPDA-anti-HBsEu 3+ has not only a higher molar ratio of BCPDA to anti-HBs, but also a relative higher biological activity, which was testified by RIA and fluorescence detection. In addition, the laser fluorescence lifetime measurement setup which was developed by us provides a design for a DSLFIA detection system. Finally, it was also proved that the fluorescence stability of BCPDA-anti-HBs-Eu 3+ and the function stability of BCPDA would ensure the system a potential application and broad prospect.
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